Related Experiment Video
Updated: Jun 10, 2026
06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency
Thomas Köhnlein1, Sabina Janciauskiene, Tobias Welte
1Hannover Medical School, Respiratory Medicine, Carl-Neuberg-Strasse 1, Hannover, Germany. koehnlein.thomas@mh-hannover.de
Therapeutic Advances in Respiratory Disease
|July 28, 2010
Summary
Diagnosing Alpha-1 antitrypsin deficiency (AATD) takes years due to patient and physician delays. Smoking worsens symptoms, while vaccinations and augmentation therapy improve outcomes for AATD patients.
Area of Science:
- Pulmonology
- Genetics
- Epidemiology
Background:
- Alpha-1 antitrypsin deficiency (AATD) is a prevalent inherited disorder, yet diagnosis remains challenging.
- Delayed diagnosis impacts patient management and disease progression.
- This study investigates diagnostic delays and factors influencing AATD course.
Purpose of the Study:
- To assess diagnostic latencies and physician involvement in Alpha-1 antitrypsin deficiency (AATD) cases.
- To evaluate the influence of smoking, vaccination, and augmentation therapy on AATD disease progression.
Main Methods:
- A written interview with 28 items was administered to patients in Germany and Austria.
- Data was collected from 596 patients, with a response rate of 44.9%.
Main Results:
- A significant delay of approximately 6 years exists between symptom onset (mean age 39.1) and AATD diagnosis (mean age 45.1).
- Patient reluctance contributed 1.4 years to the diagnostic delay, with an average of 3.2 physicians involved.
- Smoking correlated with earlier symptom onset and reduced exercise capacity.
- Pneumococcal/influenza vaccination and augmentation therapy significantly reduced exacerbations and ER visits.
Conclusions:
- A substantial delay persists in diagnosing Alpha-1 antitrypsin deficiency (AATD).
- Patient factors and the number of physicians involved contribute to diagnostic delays.
- Smoking cessation, vaccination, and augmentation therapy are crucial for managing AATD and improving patient outcomes.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...